Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M, Watanabe S, Tanaka H, Nozaki K, Arita M, Takahashi M, Shoji S, Ichikawa K, Kondo R, Aoki N, Hayashi M, Ohshima Y, Koya T, Ohashi R, Ajioka Y, Kikuchi T.
Sato M, et al. Among authors: ohashi r.
PLoS One. 2019 Apr 12;14(4):e0215292. doi: 10.1371/journal.pone.0215292. eCollection 2019.
PLoS One. 2019.
PMID: 30978241
Free PMC article.